Quince Therapeutics Reports Q3 2025 Financial Results

Quince Therapeutics ( (QNCX) ) has released its Q3 earnings. Here is a breakdown of the information Quince Therapeutics presented to its investors.

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing innovative treatments for rare diseases using its proprietary AIDE technology, which encapsulates drugs into a patient’s own red blood cells. The company operates primarily in the biotechnology sector and is headquartered in South San Francisco, California.

In its latest earnings report for the quarter ended September 30, 2025, Quince Therapeutics reported a net loss of $13.4 million, reflecting ongoing challenges in its research and development efforts. The company continues to focus on its lead asset, eDSP, aimed at treating a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T).

Key financial highlights include a decrease in cash and cash equivalents to $6.5 million from $6.2 million at the end of 2024, and a reduction in short-term investments to $19.8 million from $34.6 million. Operating expenses rose significantly to $13.4 million, driven by increased research and development costs. The company also reported an increase in the fair value of contingent consideration related to its acquisition of EryDel.

Looking ahead, Quince Therapeutics faces substantial doubt regarding its ability to continue as a going concern due to insufficient cash resources to fund operations for the next twelve months. The company plans to seek additional funding through public offerings, private financing, or strategic partnerships to support its operations and development plans.

Quince Therapeutics remains committed to advancing its drug candidates through clinical trials and obtaining necessary regulatory approvals. The management is focused on securing additional funding to ensure the continuation of its innovative research and development efforts.